國家衛生研究院 NHRI:Item 3990099045/14508
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 907503      在线人数 : 980
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14508


    题名: A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study
    作者: Bai, LY;Li, CP;Shan, YS;Chuang, SC;Chen, JS;Chiang, NJ;Chen, YY;Tsou, HH;Chuang, MH;Chiu, CF;Liu, TW;Chen, LT
    贡献者: National Institute of Cancer Research;Institute of Population Health Sciences
    摘要: Background: Elderly patients with advanced pancreatic adenocarcinoma (APC) are conceived to be frailer and susceptible to treatment toxicity that has led to disparity in lower likelihood of receiving chemotherapy and survival. Optimal chemotherapy is an unmet medical need for elderly patients with APC. Patients and methods: Patients with chemo-naive APC, age ≥70 years, and Eastern Cooperative Oncology Group (ECOG) performance score ≤2 were eligible. The treatment was consisted of biweekly gemcitabine 800 mg/m2, 10 mg/m2/min infusion on day 1 plus oral S-1 and leucovorin (40–60 and 30 mg, respectively) twice daily on days 1–7, the GSL regimen. The primary end-point was progression-free survival with an interested P1 of 5.0 months. Results: Of the 49 enrolled patients, the median age was 76 years, ECOG performance score ≥1 in 59.2%, metastatic diseases in 65.3%, Vulnerable Elders Survey-13 score ≥3 in 71.4%, and Geriatric 8 score ≤14 in 93.9%. After a median 11 cycles of treatment, the overall response rate and disease control rate were 26.5% and 75.5%, respectively. The median progression-free and overall survivals were 6.6 months (95% confidence interval [CI], 5.4–9.2) and 12.5 months (95% CI, 8.9–14.7), respectively. The most common grade 3–4 treatment-related toxicities were anaemia (20.4%), neutropenia (18.4%), and mucositis (12.2%). Patients had improved emotional function and global health status scores during the GSL treatment. Conclusion: The study met its primary end-point, which supports further investigation on the merit of GSL in Asian elderly APC patients.
    日期: 2022-09
    關聯: European Journal of Cancer. 2022 Sep;173:123-132.
    Link to: http://dx.doi.org/10.1016/j.ejca.2022.06.043
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0959-8049&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000871988800014
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85135417095
    显示于类别:[姜乃榕] 期刊論文
    [陳立宗] 期刊論文
    [劉滄梧] 期刊論文
    [鄒小蕙] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    SCP85135417095.pdf1783KbAdobe PDF207检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈